Editorial

Rev Diabet Stud, 2005, 2(4):182-186 DOI 10.1900/RDS.2005.2.182

Imbalance in Th Cell Polarization and its Relevance in Type 1 Diabetes Mellitus

Charles Sia

Department of Immunology, United Biomedical Inc., 25 Davids Drive, Hauppage, New York 11788, USA, e-mail: csia@unitedbiomedical.com.

Keywords: type 1 diabetes, Th cell, polarization

Abstract

Functional polarization of T helper (Th) subsets of lymphocytes has been implicated in promoting or conferring risk to Type 1 diabetes mellitus (T1DM) development in human and diabetic animal models. It is assumed that an immoderate preponderance of type 1 immunity establishes the prerequisite for this development. Over the past years, various immune-intervention strategies have been tested to protect diabetic animals from developing overt diabetes. These protocols implicate a protective mechanism that is attributed to a change in the set of autoreactive Th cells from their Th1 to the Th2 phenotype. The studies were aimed at improving the effectiveness of Th2 cells to secrete the principal cytokines, IL-4 and IL-10, in order to mediate protection from diabetes in NOD mice. In contrast, some immune-modulation protocols utilizing non-specific reagents report that diabetes protection is apparently attributed to preferential survival of both Th1 and Th2 cells, rather than via a shift from their Th1 to Th2 phenotypes. Even though we know that excessive immune responses against self antigens are also controlled and terminated by regulatory T cells, this article focuses on the polarization of Th effector cells and discusses the controversial findings regarding the Th1/Th2 hypothesis to draw a conclusion on its relevance in T1DM from the existing knowledge.

Fulltext: HTML , PDF (299KB)


This article has been cited by other articles:

Novel biomarkers in type 1 diabetes

Jin Y, She JX

Rev Diabet Stud 2012. 9(4):224-235

Chemokine (C-C motif) ligand 2 (CCL2) in sera of patients with type 1 diabetes and diabetic complications

Guan R, Purohit S, Wang H, Bode B, Reed JC, Steed RD, Anderson SW, Steed L, Hopkins D, Xia C, She JX

Plos One 2011. 6(4):e17822

Intramuscular delivery of a naked DNA plasmid encoding proinsulin and pancreatic regenerating III protein ameliorates type 1 diabetes mellitus

Hou WR, Xie SN, Wang HJ, Su YY, Lu JL, Li LL, Zhang SS, Xiang M

Pharmacol Res 2011. 63(4):320-327

Vitamin D and diabetes

Takiishi T, Gysemans C, Bouillon R, Mathieu C

Endocrinol Metab Clin North Am 2010. 39(2):419-446

Immunopathology of the human pancreas in type-I diabetes

Richardson SJ, Willcox A, Bone AJ, Morgan NG, Foulis AK

Semin Immunopathol 2010. Apr 28, epub ahead of print

Immunomodulatory effect of fibres, probiotics and synbiotics in different life-stages

Romeo J, Nova E, Wärnberg J, Gomez-Martinez S, Ligia LE, Marcos A

Nutr Hosp 2010. 25(3):341-349

Strategies for diabetes and pathways of vitamin D

Tuorkey MJ, Abdul-Aziz KK

Diabetes Metab Syndr 2009. 4(2):101-110

The role of the CXCL10/CXCR3 system in type 1 diabetes

Shimada A, Oikawa Y, Yamada Y, Okubo Y, Narumi S

Rev Diabet Stud 2009. 6(2):81-84

SUMO conjugation contributes to immune deviation in nonobese diabetic mice by suppressing c-Maf transactivation of IL-4

Leavenworth JW, Ma X, Mo YY, Pauza ME

J Immunol 2009. 183(2):1110-1119

Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes

Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R

J Immunol 2009. 183(2):993-1004

Genetic deficiency of Itgb2 or ItgaL prevents autoimmune diabetes through distinctly different mechanisms in NOD/LtJ mice

Glawe JD, Patrick DR, Huang M, Sharp CD, Barlow SC, Kevil CG

Diabetes 2009. 58(6):1292-1301

Analysis of islet inflammation in human type 1 diabetes

Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG

Clin Exp Immunol 2009. 155(2):173-181

Gene therapy in type 1 diabetes

Bagley J, Paez-Cortez J, Tian C, Iacomini J

Crit Rev Immunol 2008. 28(4):301-324

The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes

Mabley JG, Pacher P, Murthy KG, Williams W, Southan GJ, Salzman AL, Szabo C

J Endocrinol 2008. 198(3):581-589

Heparanase prevents the development of type 1 diabetes in non-obese diabetic mice by regulating T-cell activation and cytokines production

Bitan M, Weiss L, Zeira M, Reich S, Pappo O, Vlodavsky I, Slavin S

Diabetes Metab Res Rev 2008. 24(5):413-421

Feeding our immune system: impact on metabolism

Wolowczuk I, Verwaerde C, Viltart O, Delanoye A, Delacre M, Pot B, Grangette C

Clin Dev Immunol 2008. 2008:639803

Improved efficacy of P277 fused to heat shock protein 65 of Mycobacterium tuberculosis against diabetes in nonobese diabetic mice

Zhu A, Lu Y, Jin L, Wu J, Li T, Liu J

Sheng Wu Gong Cheng Xue Bao (Chinese Journal of Biotechnology) 2008. 24(4):640-645

Review of the literature: integrating psychoneuroimmunology into pediatric chronic illness interventions

Nassau JH, Tien K, Fritz GK

J Pediatr Psychol 2008. 33(2):195-207

IL-10 gene modified dendritic cells inhibit T helper type 1-mediated alloimmune responses and promote immunological tolerance in diabetes

Zhu H, Qiu W, Lei P, Zhou W, Wen X, He F, Li L, Dai H, Shen G, Gong F

Cell Mol Immunol 2008. 5(1):41-46

Effect of Displaying P277 Peptide on Surface of L-asparaginase on Its Antigenicity and Efficacy of Autoimmune Diabetes Prevention in NOD Mice

Zhu AH, Liu WT, Long J, Wu J, Liu JJ, Li TM

Chinese Journal of Biochemistry and Molecular Biology 2007. 23(9):730-737

Expression and purification of peptide P277 and its primary pharmacology

Zhu AH, Liu WT, Lu Y, Jin L, Wang Y, LIU JJ

J Yangzhou Univ 2007. 28(4):13-17